Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OGN
Upturn stock ratingUpturn stock rating

Organon & Co (OGN)

Upturn stock ratingUpturn stock rating
$9.86
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: OGN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $14

1 Year Target Price $14

Analysts Price Target For last 52 week
$14Target price
Low$8.01
Current$9.86
high$22.24

Analysis of Past Performance

Type Stock
Historic Profit 10.57%
Avg. Invested days 52
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.56B USD
Price to earnings Ratio 3.42
1Y Target Price 14
Price to earnings Ratio 3.42
1Y Target Price 14
Volume (30-day avg) 7
Beta 0.55
52 Weeks Range 8.01 - 22.24
Updated Date 06/30/2025
52 Weeks Range 8.01 - 22.24
Updated Date 06/30/2025
Dividends yield (FY) 0.81%
Basic EPS (TTM) 2.88

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 11.92%
Operating Margin (TTM) 21.48%

Management Effectiveness

Return on Assets (TTM) 6.98%
Return on Equity (TTM) 254.24%

Valuation

Trailing PE 3.42
Forward PE 5.03
Enterprise Value 10972166781
Price to Sales(TTM) 0.41
Enterprise Value 10972166781
Price to Sales(TTM) 0.41
Enterprise Value to Revenue 1.74
Enterprise Value to EBITDA 7.41
Shares Outstanding 259956000
Shares Floating 258734270
Shares Outstanding 259956000
Shares Floating 258734270
Percent Insiders 0.24
Percent Institutions 80.92

Analyst Ratings

Rating 3
Target Price 14
Buy 2
Strong Buy -
Buy 2
Strong Buy -
Hold 3
Sell 2
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Organon & Co

stock logo

Company Overview

overview logo History and Background

Organon & Co. was formed in 2021 as a spin-off from Merck & Co. (MRK). It focuses on women's health, biosimilars, and established brands. Organon inherited a portfolio of products and a global footprint.

business area logo Core Business Areas

  • Women's Health: Focuses on contraception, fertility treatments, and other therapies for women. Includes products like Nexplanon and NuvaRing (divested).
  • Biosimilars: Develops and commercializes biosimilar versions of established biologic drugs, covering areas such as immunology and oncology.
  • Established Brands: A broad portfolio of well-known, off-patent pharmaceutical products across various therapeutic areas including respiratory, cardiovascular, and dermatology.

leadership logo Leadership and Structure

Organon is led by Kevin Ali (CEO). The company operates with a global organizational structure, focusing on commercial execution and business development.

Top Products and Market Share

overview logo Key Offerings

  • Nexplanon: A long-acting reversible contraceptive implant. Market share is significant in the US long-acting reversible contraceptive market. Competitors include intrauterine devices (IUDs) like Mirena (BAYRY) and Skyla (BAYRY).
  • Follistim AQ Cartridge: A fertility treatment. Competition in the fertility market is fierce, with other options like Gonal-F (MRK) and various IVF procedures.
  • Bridion: A neuromuscular blockade reversal agent. Market share varies by region and is subject to hospital formulary decisions. Key competitors are sugammadex biosimilars.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly regulated and competitive, with constant innovation and patent expirations. The women's health segment is growing, fueled by increasing awareness and demand for contraception and fertility treatments. Biosimilars are gaining traction as cost-effective alternatives to biologics.

Positioning

Organon is positioned as a global healthcare company focused on women's health, biosimilars, and established brands. Its strategy involves organic growth, business development, and geographic expansion.

Total Addressable Market (TAM)

The TAM for women's health, biosimilars, and established brands is substantial, estimated to be hundreds of billions of dollars globally. Organon aims to capture a significant share through focused strategies and product development.

Upturn SWOT Analysis

Strengths

  • Established global presence
  • Diverse product portfolio
  • Focus on women's health
  • Growing biosimilars business
  • Strong cash flow generation from established brands

Weaknesses

  • Reliance on established brands facing generic competition
  • Debt burden from spin-off
  • Integration challenges post spin-off
  • Dependence on key products

Opportunities

  • Expansion into new geographies
  • Acquisition of complementary products and technologies
  • Development of innovative women's health solutions
  • Increased biosimilar adoption
  • Strategic partnerships

Threats

  • Generic competition
  • Regulatory changes
  • Pricing pressures
  • Economic downturns
  • Product liability litigation

Competitors and Market Share

competitor logo Key Competitors

  • BAYRY
  • MRK
  • PFE
  • VTRS

Competitive Landscape

Organon competes with larger pharmaceutical companies with diversified portfolios. Its focus on women's health and biosimilars provides a niche, but it also faces competition from generic manufacturers for its established brands. Brand recognition, product pipeline, regulatory approvals, and successful execution of business development strategies are very important.

Major Acquisitions

Alydia Health

  • Year: 2021
  • Acquisition Price (USD millions): 240
  • Strategic Rationale: Acquisition of Alydia Health for its innovative treatment for postpartum hemorrhage, enhancing Organon's women's health portfolio.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is tied to its success of key offerings such as Nexplanon and its Biosimilars business, plus the management of decline in established brands. Consult financial reports for specifics.

Future Projections: Future projections vary among analysts. Factors that need to be taken into account when building models are growth in Women's Health and Biosimilars as well as the effects of loss of exclusivity in its mature portfolio.

Recent Initiatives: Recent initiatives focus on business development activities, partnerships, and geographic expansion.

Summary

Organon is a pharmaceutical company with a focus on women's health, biosimilars, and established brands. It has a global presence and generates significant cash flow, but faces challenges from generic competition and debt. Opportunities lie in expanding its product portfolio and geographic reach. Organon is trying to expand its market share in Women's Health through acquisitions and its Biosimilars business. The company needs to watch for generic competition which may affect their mature portfolio revenue.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Organon SEC Filings
  • Analyst Reports
  • Industry Publications
  • Company Website

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Organon & Co

Exchange NYSE
Headquaters Jersey City, NJ, United States
IPO Launch date 2021-06-02
CEO & Director Mr. Kevin Ali
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 10000
Full time employees 10000

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.